Evogene reported that the company received a letter from the Nasdaq Stock Market indicating that the company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the company’s closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days. The Nasdaq Stock Market Rules provide the company with an additional period of 180 calendar days to regain compliance. According to the Letter, the company has until September 16, 2024, to regain compliance with the minimum bid price requirement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
